LARIMAR THERAPEUTICS, INC. Total Liabilities
LARIMAR THERAPEUTICS, INC. (LRMR) had Total Liabilities of $37.92 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-04
- 2026-06-30: Liabilities $37.92M.
- 2026-03-31: Liabilities $50.48M.
- 2025-12-31: Liabilities $67.76M.
- 2025-09-30: Liabilities $48.31M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $37.92M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $50.48M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $67.76M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $48.31M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $30.13M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $25.90M 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $28.41M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $20.62M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $25.76M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $17.36M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $14.21M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $11.24M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $11.79M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $12.67M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $15.50M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $14.35M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $12.80M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $14.12M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $14.25M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $15.87M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $13.41M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $14.23M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $14.99M 10-K · filed 2022-03-25 | |
| 2020-09-30 | $11.32M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $12.91M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $22.96M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $5.89M 10-K · filed 2021-03-04 | $27.11M 10-K · filed 2020-03-05 |
| 2019-09-30 | $33.01M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $31.75M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $27.82M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $28.49M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $28.01M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $27.78M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $27.62M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $27.29M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $7.03M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $9.22M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $8.60M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $9.89M 10-K · filed 2018-03-09 | |
| 2016-09-30 | $12.54M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $12.59M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $15.60M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $20.00M 10-K · filed 2017-03-10 | |
| 2015-09-30 | $17.75M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $16.41M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $15.05M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $13.08M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $18.44M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $11.55M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $2.92M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |